Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease

Registros relacionados

• Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
  por: Bekker, P, et al.
  Publicado em: (2007)
• Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
  por: Walters, M, et al.
  Publicado em: (2010)
• MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
  por: Ungashe, S, et al.
  Publicado em: (2008)
• A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
  por: Satish Keshav, et al.
  Publicado em: (2013-01-01)
• PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
  por: Bekker, P, et al.
  Publicado em: (2009)